\u0130leri evre hedeflenebilir s\u00fcr\u00fcc\u00fc mutasyonu olmayan k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde (KHDAK) tedavi se\u00e7enekleri s\u0131n\u0131rl\u0131 kal\u0131rken, Guangzhou \u00dcniversitesi \u00c7in T\u0131bb\u0131 \u0130lk Ba\u011fl\u0131 Hastanesi\u2019nde yap\u0131lan retrospektif bir \u00e7al\u0131\u015fma \u00f6nemli bulgular sundu. \u00c7al\u0131\u015fmada, \u00f6nceden imm\u00fcnoterapi ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 ya\u015fayan hastalarda imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri (\u0130C\u0130) ile anlotinib kombinasyonunun yeniden tedavi (rechallenge) ama\u00e7l\u0131 kullan\u0131m\u0131 de\u011ferlendirildi. Bu yakla\u015f\u0131m, \u00f6zellikle s\u00fcr\u00fcc\u00fc mutasyonu bulunmayan KHDAK hastalar\u0131nda umut vaat eden yeni bir terapi alternatifi olarak kar\u015f\u0131m\u0131za \u00e7\u0131k\u0131yor.<\/p>\n
KHDAK, d\u00fcnya genelinde en s\u0131k g\u00f6r\u00fclen akci\u011fer kanseri t\u00fcr\u00fc olup, tedavisinde biyolojik hedefe y\u00f6nelik mutasyonlar\u0131n yoklu\u011fu, hastalar\u0131n tedavi ba\u015far\u0131s\u0131n\u0131 ciddi \u015fekilde k\u0131s\u0131tlayan bir fakt\u00f6rd\u00fcr. Son y\u0131llarda imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri, kanser h\u00fccrelerine kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k sistemini harekete ge\u00e7irme ba\u015far\u0131s\u0131yla tedavi paradigmalar\u0131n\u0131 de\u011fi\u015ftirmi\u015ftir. Ancak ilk imm\u00fcnoterapi sonras\u0131nda geli\u015fen direncin \u00f6nlenmesi ve hastalar\u0131n tedavi yan\u0131t\u0131n\u0131n uzat\u0131lmas\u0131 halen \u00f6nemli bir klinik zorluktur.<\/p>\n
Bahsi ge\u00e7en retrospektif \u00e7al\u0131\u015fma, Mart 2020 \u2013 Haziran 2024 tarihleri aras\u0131nda tedavi alan 14 hasta \u00fczerinde ger\u00e7ekle\u015ftirildi. S\u00fcr\u00fcc\u00fc mutasyonu bulunmayan, ileri evre KHDAK hastalar\u0131n\u0131n t\u00fcm\u00fc \u00f6nceki imm\u00fcnoterapi tedavisine yan\u0131t verememi\u015f, hastal\u0131k ilerlemesi g\u00f6stermi\u015fti. Bu hastalar, \u0130C\u0130 ve anlotinib kombinasyonu ile yeniden tedavi alt\u0131na al\u0131nd\u0131. Anlotinib, t\u00fcm\u00f6r anjiyogenezini engelleyen ve t\u00fcm\u00f6r mikro\u00e7evresini imm\u00fcn yan\u0131t i\u00e7in elveri\u015fli hale getiren \u00e7oklu tirozin kinaz inhibit\u00f6r\u00fc olarak dikkat \u00e7ekiyor.<\/p>\n
\u00c7al\u0131\u015fman\u0131n dikkat \u00e7eken sonu\u00e7lar\u0131ndan biri objektif yan\u0131t oran\u0131n\u0131n (ORR) y\u00fczde 28,6 gibi y\u00fcksek bir de\u011ferde ger\u00e7ekle\u015fmesiydi. Bu oran\u0131n anlam\u0131, hastalar\u0131n yakla\u015f\u0131k \u00fc\u00e7te birinin belirgin t\u00fcm\u00f6r k\u00fc\u00e7\u00fclmesi ya\u015fad\u0131\u011f\u0131d\u0131r. Daha da \u00f6nemlisi hastalar\u0131n y\u00fczde 92,9\u2019u hastal\u0131k kontrol\u00fc sa\u011flayarak stabil seyir g\u00f6stermi\u015ftir. Bu oranlar, tedaviye diren\u00e7li KHDAK hastalar\u0131nda elde edilen \u00e7ok anlaml\u0131 klinik faydalar\u0131 g\u00f6zler \u00f6n\u00fcne sermektedir.<\/p>\n
Ortalama ilerlemesiz sa\u011fkal\u0131m (PFS) s\u00fcresi 11,7 ay olarak belirlendi. Bu s\u00fcre, benzer hasta gruplar\u0131nda g\u00f6r\u00fclen geleneksel tedavi s\u00fcrelerine k\u0131yasla olduk\u00e7a olumlu bir tablo \u00e7izdi. Ayr\u0131ca programlanm\u0131\u015f \u00f6l\u00fcm ligand\u0131 1 (PD-L1) pozitifli\u011fi ta\u015f\u0131yan hastalarda PFS 13,0 ay iken, PD-L1 negatif veya bilinmeyen grupta bu s\u00fcre 10,3 ay olarak \u00f6l\u00e7\u00fcld\u00fc (p=0,048). Bu bulgu, biyobelirte\u00e7lerin hastalar\u0131n tedavi yan\u0131t\u0131n\u0131 belirlemede kritik rol oynad\u0131\u011f\u0131n\u0131 vurgulamaktad\u0131r.<\/p>\n
Tedavi g\u00fcvenli\u011fi a\u00e7\u0131s\u0131ndan \u0130C\u0130 ve anlotinib kombinasyonun genellikle iyi tolere edildi\u011fi raporland\u0131. Hastalar\u0131n %7,1\u2019inde (1 ki\u015fi) sadece grade 3 seviyesinde ciddi yan etki g\u00f6r\u00fcld\u00fc. Tedaviyle ili\u015fkili \u00f6l\u00fcm ya da geri \u00e7ekilme gerektiren ciddi toksisite ya\u015fanmad\u0131. Bu da, tedavinin klinik ortamda uygulanabilirli\u011fini destekleyen \u00f6nemli bir g\u00f6stergedir.<\/p>\n
\u0130mm\u00fcnoterapi ile anlotinib kombinasyonunun ba\u015far\u0131s\u0131, anti-anjiyogenez ajanlar\u0131n\u0131n t\u00fcm\u00f6r damar yap\u0131s\u0131n\u0131 normalize edip, ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerinin t\u00fcm\u00f6r i\u00e7ine giri\u015fini kolayla\u015ft\u0131rmas\u0131ndan kaynaklan\u0131yor. Anlotinib\u2019in VEGFR, FGFR ve PDGFR gibi \u00e7ok say\u0131da hedef \u00fczerinde etkili olmas\u0131, t\u00fcm\u00f6r mikro\u00e7evresindeki bask\u0131lay\u0131c\u0131 fakt\u00f6rleri azaltarak \u0130C\u0130\u2019lerin etkinli\u011fini art\u0131r\u0131yor.<\/p>\n
Rechallenge yakla\u015f\u0131m\u0131, \u00f6nceki imm\u00fcnoterapilere kar\u015f\u0131 geli\u015fen diren\u00e7 mekanizmalar\u0131n\u0131 a\u015fmay\u0131 hedefliyor. T\u00fcm\u00f6r heterojenitesi, ba\u011f\u0131\u015f\u0131kl\u0131k ka\u00e7\u0131\u015f\u0131 ve mikro\u00e7evresel de\u011fi\u015fiklikler, uzun d\u00f6nem imm\u00fcnoterapi ba\u015far\u0131s\u0131n\u0131 engelliyor. Anlotinib ile birlikte uygulanan \u0130C\u0130 tedavisi, imm\u00fcn sistemin t\u00fcm\u00f6r \u00fczerindeki g\u00f6zetim ve kontrol kapasitesini yeniden d\u00fczenleyerek, yenilenmi\u015f bir anti-t\u00fcm\u00f6r yan\u0131t yarat\u0131yor.<\/p>\n
Hastalar\u0131n s\u00fcr\u00fcc\u00fc mutasyonu yoklu\u011fu nedeniyle EGFR ya da ALK gibi hedefli tedavi se\u00e7eneklerinden faydalanamamas\u0131, bu \u00e7al\u0131\u015fman\u0131n klinik \u00f6nemini art\u0131r\u0131yor. Bu grup hastalar genellikle kemoterapi ve imm\u00fcnoterapiye ba\u011f\u0131ml\u0131 kalmak zorunda olup, tedavi yan\u0131tlar\u0131 daha de\u011fi\u015fkendir. Dolay\u0131s\u0131yla, \u0130C\u0130-anlotinib kombinasyonunun erken klinik sonu\u00e7lar itibar\u0131yla olumlu etkisi hastalar i\u00e7in kritik bir yenilik olarak de\u011ferlendirilebilir.<\/p>\n
\u00c7al\u0131\u015fman\u0131n s\u0131n\u0131rlamalar\u0131ndan biri olan d\u00fc\u015f\u00fck hasta say\u0131s\u0131, elde edilen sonu\u00e7lar\u0131n genelle\u015ftirilmesini k\u0131s\u0131tlayabilir. Ancak retrospektif do\u011fas\u0131, retrospektif bilimsel g\u00f6zlemlerin pratikteki yerini g\u00f6stermesi a\u00e7\u0131s\u0131ndan de\u011ferlidir. Gelecekte daha geni\u015f ve kontroll\u00fc prospektif \u00e7al\u0131\u015fmalara zemin haz\u0131rlamas\u0131 a\u00e7\u0131s\u0131ndan k\u0131ymet ta\u015f\u0131maktad\u0131r.<\/p>\n
\u0130leri d\u00f6nemde bu kombinasyonun optimal kullan\u0131m zamanlamas\u0131, doz ayarlamalar\u0131 ve yeni biyobelirte\u00e7lerin tan\u0131mlanmas\u0131 tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131rmada \u00f6nem arz etmektedir. Ayr\u0131ca, b\u00fct\u00fcnsel genomik ve imm\u00fcnfenotipik analizlerin entegre edilmesi, hastan\u0131n tedavi yan\u0131t\u0131n\u0131 \u00f6ng\u00f6rme ve diren\u00e7 mekanizmalar\u0131n\u0131 anlamada yol g\u00f6sterici olacakt\u0131r.<\/p>\n
Sonu\u00e7 olarak, Guangzhou \u00dcniversitesi \u00c7in T\u0131bb\u0131 \u0130lk Ba\u011fl\u0131 Hastanesi\u2019nden gelen bu \u00f6nc\u00fc ara\u015ft\u0131rma, ileri evre s\u00fcr\u00fcc\u00fc mutasyonu olmayan KHDAK hastalar\u0131nda yeniden imm\u00fcnoterapi ve anlotinib kombinasyonunun umut vadeden bir tedavi alternatifi oldu\u011funu ortaya koyuyor. Elde edilen sonu\u00e7lar, geni\u015f \u00e7apl\u0131 klinik \u00e7al\u0131\u015fmalar i\u00e7in temel te\u015fkil ederek hastalar\u0131n ya\u015fam s\u00fcreleri ve ya\u015fam kalitesinde \u00f6nemli geli\u015fmelerin \u00f6n\u00fcn\u00fc a\u00e7abilir.<\/p>\n
Akci\u011fer kanseri, d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131n ya\u015fam\u0131n\u0131 tehdit etmeye devam ederken, imm\u00fcnoterapi ve anjiyogenez inhibit\u00f6rlerinin kombinasyonu yeni bir tedavi \u00e7a\u011f\u0131n\u0131n habercisi olabilir. Bu entegre yakla\u015f\u0131m, hastal\u0131\u011f\u0131n biyolojik karma\u015f\u0131kl\u0131\u011f\u0131n\u0131 hedef alarak diren\u00e7 mekanizmalar\u0131n\u0131 a\u015fmay\u0131 ama\u00e7lar ve b\u00f6ylece hastalar\u0131n tedavi s\u00fcre\u00e7lerinde daha uzun s\u00fcreli kontroll\u00fc hastal\u0131k durumu sa\u011flama potansiyeline sahiptir.<\/p>\n
Ger\u00e7ek d\u00fcnya klinik verileri ile molek\u00fcler biyoloji alan\u0131ndaki ilerlemelerin birle\u015ftirilmesi, benimsenen bu tedavi rezonsanslar\u0131n\u0131n maksimum potansiyelini ortaya \u00e7\u0131karacakt\u0131r. Bu s\u00fcrecin ba\u015far\u0131l\u0131 olmas\u0131 i\u00e7in multidisipliner ekiplerin i\u015f birli\u011fi ve s\u00fcrekli klinik ara\u015ft\u0131rmalar\u0131n s\u00fcrd\u00fcr\u00fclmesi hayati \u00f6nem ta\u015f\u0131maktad\u0131r.<\/p>\n
Bu \u00e7al\u0131\u015fma, klinik prati\u011fe yeni stratejilerin dahil edilmesinin gereklili\u011fini bir kez daha hat\u0131rlatmakta ve tedavi ba\u015far\u0131s\u0131n\u0131n art\u0131r\u0131lmas\u0131 ad\u0131na yenilik\u00e7i yakla\u015f\u0131mlar\u0131n ka\u00e7\u0131n\u0131lmazl\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. \u0130mm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri ile anlotinib kombinasyonu, diren\u00e7le m\u00fccadelede etkili silah olarak kullan\u0131mda artan bir ivme kazanabilir.<\/p>\n
Sonu\u00e7 itibar\u0131yla, Guangzhou \u00dcniversitesi \u00c7in T\u0131bb\u0131 \u0130lk Ba\u011fl\u0131 Hastanesi taraf\u0131ndan y\u00fcr\u00fct\u00fclen bu retrospektif \u00e7al\u0131\u015fma, kombinasyon imm\u00fcnoterapilerinin KHDAK y\u00f6netiminde etkin ve g\u00fcvenli alternatifler olarak de\u011ferlendirilmesinin \u00f6nemini vurgulamaktad\u0131r. Bu bulgular, ileri evre akci\u011fer kanseri tedavisinde yeni ufuklar a\u00e7arak tedavi \u015fekillerinin yeniden \u015fekillenmesine \u00f6nc\u00fcl\u00fck edecektir.<\/p>\n
—<\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: \u0130mm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri ile anlotinib kombinasyonunun, ileri evre ve s\u00fcr\u00fcc\u00fc mutasyonu olmayan k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanseri hastalar\u0131nda imm\u00fcnoterapi sonras\u0131 yeniden tedavi (rechallenge) amac\u0131yla g\u00fcvenlik ve etkinli\u011finin retrospektif analizi.<\/p>\n Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Safety and efficacy of rechallenge with immune checkpoint inhibitors and anlotinib in advanced non-small cell lung cancer without targetable driver mutations: a retrospective analysis.<\/p>\n Web References<\/strong>: https:\/\/doi.org\/10.1186\/s12885-025-14209-6<\/p>\n Doi Referans<\/strong>: https:\/\/doi.org\/10.1186\/s12885-025-14209-6<\/p>\n Resim Credits<\/strong>: Scienmag.com<\/p>\n Anahtar Kelimeler<\/strong>: \u0130leri evre k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanseri tedavisi, anlotinib, imm\u00fcnoterapi, imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri, kombine tedavi, diren\u00e7 mekanizmalar\u0131, biyobelirte\u00e7ler, PD-L1, rechallenge stratejileri, retrospektif \u00e7al\u0131\u015fma, antianjiyogenez, tedavi g\u00fcvenli\u011fi, klinik etkinlik<\/p>\n","protected":false},"excerpt":{"rendered":" \u0130leri evre hedeflenebilir s\u00fcr\u00fcc\u00fc mutasyonu olmayan k\u00fc\u00e7\u00fck h\u00fccre d\u0131\u015f\u0131 akci\u011fer kanserinde (KHDAK) tedavi se\u00e7enekleri s\u0131n\u0131rl\u0131 kal\u0131rken, Guangzhou \u00dcniversitesi \u00c7in T\u0131bb\u0131 \u0130lk Ba\u011fl\u0131 Hastanesi\u2019nde yap\u0131lan retrospektif bir \u00e7al\u0131\u015fma \u00f6nemli bulgular sundu. \u00c7al\u0131\u015fmada, \u00f6nceden imm\u00fcnoterapi ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 ya\u015fayan hastalarda imm\u00fcn kontrol noktas\u0131 inhibit\u00f6rleri (\u0130C\u0130) ile anlotinib kombinasyonunun yeniden tedavi (rechallenge) ama\u00e7l\u0131 kullan\u0131m\u0131 de\u011ferlendirildi. Bu yakla\u015f\u0131m, \u00f6zellikle s\u00fcr\u00fcc\u00fc mutasyonu…<\/p>\n","protected":false},"author":1,"featured_media":5681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[7539,7541,7538,7542,7540],"tmauthors":[],"class_list":{"0":"post-5680","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-anlotinib-ve-immun-kontrol-noktasi-inhibitorleri-kombinasyonu","9":"tag-immunoterapi-direncinde-anlotinib-kullanimi","10":"tag-kucuk-hucre-disi-akciger-kanserinde-immunoterapi-tekrar-tedavisi","11":"tag-pd-l1-biyobelirteci-ve-akciger-kanseri-tedavi-yaniti","12":"tag-surucu-mutasyonu-olmayan-khdak-tedavi-stratejileri"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/Lung-Kanserinde-Immunoterapi-ve-Anlotinib-Tekrar-Tedavisi-1747112383.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=5680"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5680\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/5681"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=5680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=5680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=5680"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=5680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}